简化老年综合评估系统在老年弥漫大B细胞淋巴瘤患者中的多中心回顾性临床研究
该研究回顾性分析江苏省6家医院2018年1月至2022年12月初诊的219例年龄≥60岁弥漫大B细胞淋巴瘤患者,按简化老年综合评估(sGA)分为适合组101例、不适合组103例和脆弱组15例。结果显示sGA可有效预测治疗不良反应、疗效、疾病进展及长期生存,三组缓解率、疾病进展率和2年总生存率差异有统计学意义。
要点
- sGA将老年DLBCL患者分为适合组101例(46.1%)、不适合组103例(47.0%)和脆弱组15例(6.8%)。
- 适合组、不适合组和脆弱组缓解率分别为74.3%、46.6%和20.0%(χ²=25.249,P<0.001)。
- 三组2年无进展生存率差异无统计学意义(P=0.399)。
核心结论
- sGA可有效预测老年DLBCL患者的治疗相关不良反应、疗效、疾病进展及长期生存。
研究设计与样本
- 回顾性分析2018年1月至2022年12月在江苏省内6家医院就诊的年龄≥60岁的初诊DLBCL患者219例,分析sGA评分与临床特征、疗效和预后的关系。
主要发现
- 219例患者的中位年龄68(60~87)岁。
- 根据sGA评分标准,适合组、不适合组和脆弱组分别为101例(46.1%)、103例(47.0%)和15例(6.8%)。
- 三组的>2级血液学不良反应发生率相似(47.5% vs 41.7% vs 46.7%,χ²=0.712,P=0.700)。
- 脆弱组患者的>2级胃肠道、肺不良反应及感染发生率高于适合组和不适合组,但差异无统计学意义(均P>0.05)。
- 适合组、不适合组和脆弱组的缓解率分别为74.3%、46.6%和20.0%(χ²=25.249,P<0.001),疾病进展率分别为5.9%、11.7%和26.7%(χ²=6.763,P<0.05),2年总生存率分别为92.1%(95% CI 86.6%~97.9%)、77.6%(95% CI 69.5%~86.6%)、70.1%(95% CI 49.4%~99.6%)(P<0.05),2年无进展生存率分别为76.8%(95% CI 67.0%~84.8%)、69.7%(95% CI 61.8%~82.0%)、65.7%(95% CI 53.3%~100%),差异无统计学意义(P=0.399)。
关键数值与推荐
- sGA评分标准将老年DLBCL患者分为适合组、不适合组和脆弱组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the predictive value of simplified geriatric assessment (sGA) in elderly Chinese patients diagnosed with diffuse large B-cell lymphoma (DLBCL) . Methods: It retrospectively analyzed the relationships of sGA with the clinical characteristics, outcome, and prognosis of 219 patients aged ≥60 years who were newly diagnosed with DLBCL at six hospitals in Jiangsu province between January 2018 and December 2022. Results: The median age of 219 patients was 68 years (60-87 years). According to the sGA system criteria, 101 (46.1%), 103 (47.0%), and 15 (6.8%) elderly patients with DLBCL were categorized as fit, unfit, and frail, respectively. The most common adverse reactions after chemotherapy were hematologic, and the incidence of grade >2 hematologic adverse reactions was similar among the three groups (47.5% vs 41.7% vs 46.7%, respectively; χ(2)=0.712, P=0.700). Compared with the fit and unfit groups, the frail group showed tendencies toward for higher proportions of grade >2 gastrointestinal, pulmonary, and infectious adverse reactions (P>0.05 for all). The fit, unfit, and frail groups had respective remission rates of 74.3%, 46.6%, and 20.0% (χ(2)=25.249, P<0.001) ; disease progression rates of 5.9%, 11.7%, and 26.7% (χ(2)=6.763, P<0.05) ; 2-year overall survival rates of 92.1% (95% CI 86.6% to 97.9%), 77.6% (95% CI 69.5% to 86.6%), and 70.1% (95% CI 49.4% to 99.6%) (P<0.05) ; and 2-year progression-free survival rates of 76.8% (95% CI 67.0% to 84.8%), 69.7% (95% CI 61.8% to 82.0%), and 65.7% (95% CI 53.3% to 100%) (P=0.399) . Conclusion: sGA can effectively predict treatment adverse effects and efficacy, disease progression, and long-term survival in elderly DLBCL. 目的: 评价简化老年综合评估(sGA)在老年弥漫大B细胞淋巴瘤(DLBCL)患者中的预测价值。 方法: 回顾性分析2018年1月至2022年12月在江苏省内6家医院就诊的年龄≥60岁的初诊DLBCL患者219例,分析sGA评分与临床特征、疗效和预后的关系。 结果: 219例患者的中位年龄68(60~87)岁。根据sGA评分标准,将老年DLBCL患者分为适合组、不适合组和脆弱组,分别为101例(46.1%)、103例(47.0%)和15例(6.8%)。接受化疗后发生血液学不良反应最常见,三组的>2级血液学不良反应发生率相似(47.5%、41.7%和46.7%,χ(2)=0.712,P=0.700)。脆弱组患者的>2级胃肠道、肺不良反应及感染发生率高于适合组和不适合组,但差异无统计学意义(均P>0.05)。适合组、不适合组和脆弱组的缓解率分别为74.3%、46.6%和20.0%(χ(2)=25.249,P<0.001),疾病进展率分别为5.9%、11.7%和26.7%(χ(2)=6.763,P<0.05),2年总生存率分别为92.1%(95% CI 86.6%~97.9%)、77.6%(95% CI 69.5%~86.6%)、70.1%(95% CI 49.4%~99.6%)(P<0.05),2年无进展生存率分别为76.8%(95% CI 67.0%~84.8%)、69.7%(95% CI 61.8%~82.0%)、65.7%(95% CI 53.3%~100%),差异无统计学意义(P=0.399)。 结论: sGA可有效预测老年DLBCL的治疗相关不良反应、疗效、疾病进展及长期生存。.
引用
- Leng JY, Cai YH, Ge XP, et al. [A multicenter retrospective clinical study of a simplified comprehensive geriatric assessment system in elderly patients with diffuse large B-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40134194. doi:10.3760/cma.j.cn121090-20241121-00467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。